RE: HEPH valuation in relation to 2 new factors, any educated guesses here whether this might mean something?
HEPH has been hanging around 9 or 10 for awhile, is a smaller cap, and does not get much attention.
Question is: is this just routine or should we suspect something unusual is up., for example on African HIV trials?
2 items
1. Wall St Journal front page-left- Sept 28 article referring to small study at Mass General Hospital - with the conclusion that an Immune based strategy may now be possible against HIV. The article fails to mention HEPH in any way, which seems odd as they are probably one of the few focusing on this immune based approach.
2. Sept 29 - 3 key new hires to HEPH:Hollis-Eden Pharmaceuticals Announces New Hires in Research and Development - 2 of these hires rather noteworthy I believe
SAN DIEGO, Sept. 29 /PRNewswire/ -- Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH - news) today announced the appointments of Steven White, Ph.D., to the position of Director of Medicinal Chemistry; David Skarinsky as a Director of Clinical Research; and Alan Villanueva to the position of Senior Clinical Research Manager.
Dr. White joins Hollis-Eden after serving as Principle Investigator of Medicinal Chemistry and as Senior Research Investigator for Ligand Pharmaceuticals in San Diego. He also served as a Senior Research Chemist for Schering Research of Bloomfield, New Jersey. Dr. White received his Ph.D. in Organic Chemistry at Colorado State University, and he conducted post-doctoral work at the University of California, Irvine.
Mr. Skarinsky joins Hollis-Eden from Quintiles Inc., where he was Director of Clinical Operations. He has 13 years experience in multi-disciplinary, multi-national (US, Japan, Western Europe and Australia) clinical development, drug trials and regulatory filing experience. The Company also appointed Alan Villanueva to the position of Senior Clinical Research Manager. Mr. Villanueva joins the Company's clinical development team from Molecular Biosystems, Inc., where he was a Clinical Research Associate.
............... |
